Pharus Diagnostics ("PharusDx") has announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic cancer. This collaboration aims to develop a non-invasive liquid biopsy test called OncoSweep™, leveraging advanced technology to detect pancreatic cancer in its early stages accurately.

Pancreatic cancer is projected to become the second leading cause of cancer-related deaths in the United States within the next decade, with a dismal five-year survival rate. However, the deep-seated nature of the pancreas within the body often leads to late-stage diagnoses, as early-stage symptoms may be absent.

Under the agreement, PharusDx gains access to microRNA biomarkers that have demonstrated significant improvements in sensitivity and specificity for pancreatic cancer detection. This breakthrough offers hope for earlier and more accurate diagnoses, potentially leading to better patient outcomes.

Bowei Lee, Chairman of PharusDx, expressed enthusiasm for the potential impact of this technology on patient care, particularly for those eligible for surgical interventions. Meanwhile, Dr. Ajay Goel of City of Hope highlighted the significance of this collaboration in advancing non-invasive cancer detection methods, emphasizing the urgency of addressing the growing burden of pancreatic cancer globally.

The OncoSweep™ test, powered by machine learning algorithms, promises to revolutionize pancreatic cancer screening by offering a painless, cost-effective, and easily repeatable option. By identifying specific biomarker signatures unique to cancer patients, this test aims to improve upon current screening methods, particularly for asymptomatic individuals with known risk factors.

PharusDx remains committed to advancing cancer screening technologies and looks forward to a future where early detection becomes the norm, leading to improved outcomes for patients worldwide.